Alvotech (ALVO) Jumped, But What Is Driving Attention Now?

Why Barclays’ Upgrade Put Alvotech Back on Investors’ Radar

Alvotech (ALVO) moved back into focus after Barclays upgraded the stock following a U.S. FDA inspection of the Reykjavik manufacturing site that concluded with a Voluntary Action Indicated outcome.

That classification resolved a regulatory overhang and allowed the biosimilar producer to resubmit biologics applications tied to several high profile reference drugs. For investors, attention now turns to how those regulatory review milestones might influence sentiment around Alvotech over the coming year.

Recent trading reflects that shift in tone. Alvotech’s 1 day share price return of 9.93% and 30 day share price return of 47.12% sit against a 1 year total shareholder return that declined 25.51%. This suggests that short term momentum is building after a tougher run for longer term holders.

Scan how Alvotech’s regulatory reset compares to other potential breakout ideas in our curated list of 16 high quality undiscovered gems across global markets.

The recent surge in Alvotech looks like a clean reaction to the FDA overhang clearing, but sentiment can move faster than fundamentals. How does the current valuation compare with the business that actually exists today?

Most Popular Narrative: 14% Undervalued

Alvotech’s most followed narrative pegs fair value at $6.80 per share, compared with a last close of $5.87. This frames the recent bounce as only a partial catch up to that estimate.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step change in topline revenue once approvals are secured.

See why 13 investors see Alvotech as 14% undervalued.

Result: Fair Value of $6.80 (UNDERVALUED)

Still, the bullish Alvotech story leans heavily on unpredictable regulatory milestones and partner execution. These factors could delay approvals and slow the commercial ramp if they disappoint.

Find out about the key risks to this Alvotech narrative.

Next Steps

Mixed signals around Alvotech’s reset can feel confusing, so move quickly from headline to hard numbers and weigh both sides of the story using 3 key rewards and 2 important warning signs.

Looking for more ideas beyond Alvotech?

Do not stop with one ticker when the market constantly throws up new stories. A wider watchlist gives you options when sentiment shifts.

• Target resilient balance sheets and steady fundamentals with a diversified list of solid balance sheet and fundamentals (23 results) that can help you stress test your portfolio.
• Hunt for mispriced quality and compare Alvotech with a focused 33 high quality undervalued stocks that highlights companies where fundamentals and price do not yet line up.
• Secure potential cash flow and reduce reliance on capital gains by scanning a curated 6 dividend fortresses that focuses on higher yielding payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com